Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

Cytos Biotechnology

Status and phase: Completed; Phase 2

Conditions: Perennial Allergy to House Dust Mite and/or Cat

Treatments: Drug: CYT003-QbG10

Study type: Interventional

Funder types: Industry

Identifiers

NCT00575003

CYT003-QbG10 08

Details and patient eligibility

About

The purpose of the study is to test the efficacy of a vaccine against house dust mite and/or cat allergy compared to placebo in adult patients.

Enrollment: 64 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mild to moderate perennial allergic rhinoconjunctivitis due to hypersensitization towards house dust mite and/or cat allergens

Exclusion criteria

• Clinical relevant other allergies (perennial or seasonal) that could potentially interfere with the patient's study treatment schedule or assessments.
• Use of any concomitant medication that could affect the patient's study treatment response or assessment results.
• Any clinically relevant concomitant disease as judged by the investigator.
• Pregnancy or female planning to become pregnant during the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

64 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: CYT003-QbG10

2

Placebo Comparator group

Treatment:

Drug: CYT003-QbG10